Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)

Daniel Betticher, David C. Linch(University of Oxford), John Radford(Manchester Academic Health Science Centre), T.J. Kovascovics(Swiss Group For Clinical Cancer Research), Susanne Cina(Swiss Group For Clinical Cancer Research), Rudolf Maibach(The Coordinating Center), Ulrich Kaiser(University of Applied Sciences Landshut), Giovanni Martinelli(University of Bologna), Martin J.S. Dyer(University of Leicester), Thomas Cerny(Kantonsspital St. Gallen), Martin Kaufmann(Robert Bosch Hospital), J Thaddeus Beck(German Inflammatory Bowel Diseases Study Group), Sergio Cogliatti(Franklin University), W. E. Aulitzky(German Inflammatory Bowel Diseases Study Group), A. von Rohr(Swiss Group For Clinical Cancer Research)
Annals of Oncology
August 3, 2006
10.1093/annonc/mdl153
Cited by 42

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts
|Blood|2015|1.2k